| Author | Year | No. of patients | Design | Test used | Main outcome |
| Almohmmed A [26] | Heart 1998 | 27 | Observational | PET | 52% of viability suitable for revascularization |
| Auerbach MA [27] | Circulation 1999 | 283 | Observational | PET | 55% of viability, 27% improved with revasculrization |
| Schinkel AFL [28] | Heart 2002 | 104 | A retrospective observational study | SPECT | 61% of viability improved with revasculrization |
| Schinkel AFL [29] | Am J Cardiol 2001 | 150 | Observational | DSE | 37% of viability improved with revasculrization |
| Bonow RO [17] | N Engl J Med 2011 (Stich) | 601 | Randomized controlled trial | DSE and SPECT | No significant interaction between viability status and treatment assignment with respect to mortality |
| Beanlands RS [23] | Am J Cardiol 2007 (PARR-2) | 218 | Randomized controlled trial | PET | Did not demonstrate a significant reduction in cardiac events in patients with LV dysfunction and coronary disease for FDG PET-assisted management versus standard care |
| Cleland JGF [25] | Eur J Heart Fail 2011 (HEART) | 138 | Unblinded randomized controlled | DSE and NUCLEAR | There were no differences in mortality by intention-to-treat with use of viability testing |
| Stipac AV [30] | Heart 2013 | 115 | Prospective observational cohort study. | DSE | It appears that patients with LV dysfunction, but without viable myocardium, may also benefit from myocardial revascularisation. |
| Shah DJ [31] | JAMA 2013 | 1055 | Observational prospective | MRI | Among patients with CAD referred for CMR and found to have regional wall thinning, limited scar burden was present in 18% and was associated with improved contractility and resolution of wall thinning after revascularization |